Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8
Status:
COMPLETED
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The study should evaluate the biological distribution of 99mTc-DB8 in patients with prostate cancer and breast cancer.
The primary objective are:
1. To assess the distribution of \[99mTc\]Tc- DB8 in normal tissues and tumors at different time intervals.
2. To evaluate dosimetry of \[99mTc\]Tc- DB8.
3. To study the safety and tolerability of the drug \[99mTc\]Tc- DB8 after a single injection in a diagnostic dosage.
The secondary objective are:
1\. To compare the obtained \[99mTc\]Tc- DB8 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients.
Phase:
PHASE1
Details
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences